Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Bloom Energy (NYSE: BE) hit it out of the park in October, delivering on every metric that matters and forging a multibillion ...